Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review

키워드

참고문헌 (57)

1. "WHO coronavirus (COVID-19) dashboard" (2021)[URL]
2. Stadler K, "SARS : beginning to understand a new virus", Nat Rev Microbiol, 1, pp.209~218 (2003)
3. Janeway Jr CA, "Immunobiology: the immune system in health and disease" (2001), Garland Science
4. "Tracking SARS-CoV-2 variants" (2021)[URL]
6. "COVID data tracker: variant proportions" (2022)[URL]
7. Beatty AL, "Analysis of COVID-19 vaccine type and adverse effects following vaccination", JAMA Netw Open, 4, pp.e2140364~ (2021)
8. Bansal A, "Safety, immunogenicity, efficacy and effectiveness of inactivated influenza vaccines in healthy pregnant women and children under 5 years : an evidence-based clinical review", Front Immunol, 12, pp.744774~ (2021)
9. Pepin S, "Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months : a multi-season randomised placebo-controlled trial in the Northern and Southern hemispheres", Vaccine, 37, pp.1876~1884 (2019)
10. Ott JJ, "Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations", Int J Infect Dis, 17, pp.e939~e944 (2013)
11. "Polio vaccination" (2018)[URL]
12. Zhang Y, "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years : a randomised, double-blind, placebo-controlled, phase 1", 2 clinical trial, 2021, pp.21, 181~192
13. Tanriover MD, "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine(CoronaVac) : interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey", Lancet, 398, pp.213~222 (2021)
14. Wang H, "Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2", Cell, 182, pp.713~721 (2020)
15. Xia S, "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV : a randomised, double-blind, placebo-controlled, phase 1", 2 trial, 2021, pp.21, 39~51
16. Guo W, "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older : a randomized, double-blind, placebo-controlled, phase 1", 2 trial, 2021, pp.38, 101010~
17. Li XN, "Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou : a test-negative case-control real-world study", Emerg Microbes Infect, 10, pp.1751~1759 (2021)
18. Russell WC, "Adenoviruses : update on structure and function", J Gen Virol, 90(Pt 1), pp.1~20 (2009)
19. Buller RE, "A phase I", II trial of rAd, Cancer Gene Ther, pp.2002, 9[DOI]
20. Tatsis N, "Adenoviruses as vaccine vectors", Mol Ther, 10, pp.616~629 (2004)
21. Dolzhikova IV, "Safety and immunogenicity of GamEvac-Combi, a heterologous VSV-and Ad5-vectored Ebola vaccine : an open phase I", II trial in healthy adults in Russia, 2017, pp.13, 613~620
22. Astuti I, "Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) : an overview of viral structure and host response", Diabetes Metab Syndr, 14, pp.407~412 (2020)
23. Folegatti PM, "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1", 2, single-blind, randomised controlled trial, 2020, pp.396, 467~478
24. Voysey M, "Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19(AZD1222)vaccine : a pooled analysis of four randomised trials", Lancet, 397, pp.881~891 (2021)
25. SadoffJ, "Interim results of a phase 1-2a trial of Ad26. COV2. S COVID-19 vaccine", N Engl J Med, 384, pp.1824~1835 (2021)
26. Bos R, "Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses", NPJ Vaccines, 5, pp.91~ (2020)
27. Logunov DY, "Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine : an interim analysis of a randomised controlled phase 3 trial in Russia", Lancet, 397, pp.671~681 (2021)
28. Eichinger S, "Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination : reply", N Engl J Med, 385, pp.e11~ (2021)
29. "Emergency preparedness and response: cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson & Johnson COVID-19 vaccine" (2021)[URL]
30. Polack FP, "Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
31. Wrapp D, "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation", Science, 367, pp.1260~1263 (2020)
32. Thomas SJ, "Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months", N Engl J Med, 385, pp.1761~1773 (2021)
33. Sahin U, "BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans", Nature, 595, pp.572~577 (2021)
34. Ahmed SF, "SARS-CoV-2 T cell responses elicited by COVID-19 vaccines or infection are expected to remain robust against Omicron", Viruses, 14, pp.79~ (2022)
35. Tarke A, "Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals", Cell Rep Med, 2, pp.100355~ (2021)
36. Stanojevic M, "Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains", Cytotherapy, 24, pp.10~15 (2022)
37. Lopez Bernal J, "Effectiveness of COVID-19 vaccines against the B. 1. 617. 2(Delta)variant", N Engl J Med, 385, pp.585~594 (2021)
38. Groß R, "Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants", EBioMedicine, 75, pp.103761~ (2022)
39. Bar-On YM, "Protection against COVID-19 by BNT162b2 booster across age groups", N Engl J Med, 385, pp.2421~2430 (2021)
40. Perrie Y, "Designing liposomal adjuvants for the next generation of vaccines", Adv Drug Deliv Rev, 99(Pt A), pp.85~96 (2016)
41. Anderson EJ, "Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults", N Engl J Med, 383, pp.2427~2438 (2020)
42. El Sahly HM, "Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase", N Engl J Med, 385, pp.1774~1785 (2021)
43. Self WH, "Comparative effectiveness of moderna, Pfizer-BioNTech, and Janssen(Johnson & Johnson)vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions : United States, March-August 2021", MMWR Morb Mortal Wkly Rep, 70, pp.1337~1343 (2021)
44. Castiello T, "COVID-19 and myocarditis : a systematic review and overview of current challenges", Heart Fail Rev, 27, pp.251~261 (2022)
45. Barda N, "Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting", N Engl J Med, 385, pp.1078~1090 (2021)
46. Colella G, "Bell’s palsy following COVID-19 vaccination", J Neurol, 268, pp.3589~3591 (2021)
47. Repajic M, "Bell’s Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy", Brain Behav Immun Health, 13, pp.100217~ (2021)
48. OzonoffA, "Bell’s palsy and SARS-CoV-2 vaccines", Lancet Infect Dis, 21, pp.450~452 (2021)
49. Teixeira FM, "DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB", c mice, 2006, pp.13, 930~935
50. Kodihalli S, "Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines", Vaccine, 18, pp.2592~2599 (2000)
51. Rai N, "Development of rabies DNA vaccine using a recombinant plasmid", Acta Virol, 49, pp.207~210 (2005)
52. Tebas P, "Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2 : a preliminary report of an open-label, Phase 1 clinical trial", EClinicalMedicine, 31, pp.100689~ (2021)
53. Pallesen J, "Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen", Proc Natl Acad Sci U S A, 114, pp.E7348~E7357 (2017)
54. Magnusson SE, "Matrix-M™ adjuvant enhances immunogenicity of both protein-and modified vaccinia virus Ankara-based influenza vaccines in mice", Immunol Res, 66, pp.224~233 (2018)
55. Reimer JM, "Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen", PLoS One, 7, pp.e41451~ (2012)
56. Heath PT, "Safety and efficacy of NVX-CoV2373 COVID-19 vaccine", N Engl J Med, 385, pp.1172~1183 (2021)
57. Arunachalam PS, "Adjuvanting a subunit COVID-19 vaccine to induce protective immunity", Nature, 594, pp.253~258 (2021)

관련 논문AI추천